Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2CNS 2Other hematologic neoplasm 1

Conditions

Neoplasms 2Glioma 2Brain Neoplasms 2Disease Progression 1

Interventions

Temozolomide 147Radiotherapy 91Cyclophosphamide 53Magnetic Resonance Spectroscopy 43Radiation 42Bevacizumab 38Irinotecan 34Filgrastim 29Radiosurgery 27Specimen Handling 25Nivolumab 25Carboplatin 24Topotecan 23Etoposide 22fludarabine 20Surgical Procedures, Operative 20pembrolizumab 19Vorinostat 18Vincristine 18Melphalan 17Granulocyte Colony-Stimulating Factor 17sargramostim 15Peripheral Blood Stem Cell Transplantation 14Ipilimumab 14Drug Therapy 13temsirolimus 12Sirolimus 12Radiotherapy, Intensity-Modulated 12O(6)-benzylguanine 12Everolimus 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × enzastaurin × CNS × Clear all
NCT00108056 2019-12-05

Enzastaurin to Treat Recurrent Brain Tumor

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
26 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms, Disease Progression

NCT01445119 2013-08-28

A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas

Eli Lilly and Company

Phase 1 Completed
58 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡